|
Risk of prostate cancer incidence
| | | | | | |
|
Any NSAIDs
| | | | | | |
|
Studies of total prostate cancer
|
11
|
0.90 (0.75, 1.07)
|
0.25
|
Random
|
93.5
|
<0.001
|
|
Case–control studies
|
8
|
0.97 (0.79, 1.20)
|
0.78
|
Random
|
93.8
|
<0.001
|
|
Cohort studies
|
3
|
0.71 (0.47, 1.07)
|
0.10
|
Random
|
81.4
|
0.005
|
|
Studies in North America
|
6
|
0.73 (0.60, 0.88)
|
0.001
|
Random
|
79.6
|
<0.001
|
|
Studies in Europe
|
5
|
1.29 (1.25, 1.34)
|
<0.001
|
Fixed
|
37.2
|
0.17
|
|
Studies of advanced prostate cancer
|
5
|
0.86 (0.52, 1.40)
|
0.54
|
Random
|
94.2
|
<0.001
|
|
Aspirin
| | | | | | |
|
Studies of total prostate cancer
|
23
|
0.92 (0.87, 0.97)
|
0.002
|
Random
|
66.2
|
<0.001
|
|
Case–control studies
|
13
|
0.92 (0.85, 0.99)
|
0.040
|
Random
|
63.7
|
0.001
|
|
Cohort studies
|
10
|
0.91 (0.83, 0.99)
|
0.040
|
Random
|
71.7
|
<0.001
|
|
Studies from North America
|
16
|
0.92 (0.86, 0.97)
|
0.003
|
Random
|
53.7
|
0.006
|
|
Studies from Europe
|
7
|
0.94 (0.82, 1.08)
|
0.40
|
Random
|
80.7
|
<0.001
|
|
High quality studies
|
8
|
0.89 (0.81, 0.98)
|
0.022
|
Random
|
77.2
|
<0.001
|
|
Long-term aspirin use (≥4 years)
|
8
|
0.88 (0.79, 0.99)
|
0.038
|
Random
|
66.8
|
0.004
|
|
Studies of advanced prostate cancer
|
13
|
0.81 (0.73, 0.89)
|
<0.001
|
Fixed
|
23.9
|
0.20
|
|
Case–control studies
|
7
|
0.84 (0.73, 0.98)
|
0.025
|
Fixed
|
23.7
|
0.18
|
|
Cohort studies
|
6
|
0.77 (0.67, 0.89)
|
<0.001
|
Fixed
|
23.5
|
0.26
|
|
Studies from North America
|
9
|
0.82 (0.75, 0.89)
|
<0.001
|
Fixed
|
14.0
|
0.32
|
|
Studies from Europe
|
4
|
0.88 (0.75, 1.03)
|
1.22
|
Fixed
|
48.2
|
0.12
|
|
High quality studies
|
6
|
0.81 (0.72, 0.92)
|
0.002
|
Fixed
|
38.1
|
0.152
|
|
Studies of non-advanced prostate cancer
|
6
|
0.96 (0.87, 1.07)
|
0.460
|
Fixed
|
33.6
|
0.177
|
|
Non-aspirin NSAIDs
| | | | | | |
|
Studies of total prostate cancer
|
17
|
1.01 (0.90, 1.13)
|
0.86
|
Random
|
90.1
|
<0.001
|
|
Case–control studies
|
11
|
0.97 (0.81, 1.17)
|
0.74
|
Random
|
93.0
|
<0.001
|
|
Cohort studies
|
6
|
1.07 (0.95, 1.20)
|
0.25
|
Random
|
69.6
|
0.006
|
|
Studies from North America
|
11
|
0.94 (0.85, 1.05)
|
0.28
|
Random
|
68.8
|
<0.001
|
|
Studies from Europe
|
6
|
1.18 (1.06, 1.32)
|
0.002
|
Random
|
71.1
|
0.004
|
|
Studies of advanced prostate cancer
|
9
|
0.99 (0.77, 1.28)
|
0.97
|
Random
|
81.6
|
<0.001
|
|
Studies of non-advanced prostate cancer
|
3
|
1.00 (0.90, 1.12)
|
0.943
|
Fixed
|
0.0
|
0.897
|
|
Any COX2 inhibitors
| | | | | | |
|
Studies of total prostate cancer
|
5
|
1.10 (0.90, 1.33)
|
0.36
|
Random
|
48.7
|
0.099
|
|
Studies of advanced prostate cancer
|
3
|
1.20 (0.79, 1.83)
|
0.40
|
Fixed
|
0.0
|
0.87
|
|
Risk of prostate cancer-specific mortality
| | | | | | |
|
Any NSAIDs (including aspirin use alone)
| | | | | | |
|
Studies of total prostate cancer
|
8
|
1.00 (0.68, 1.47)
|
0.99
|
Random
|
95.3
|
<0.001
|
|
Aspirin
| | | | | | |
|
Studies of total prostate cancer
|
6
|
0.86 (0.78, 0.96)
|
0.005
|
Fixed
|
39.2
|
0.15
|
|
Studies from North America
|
3
|
0.85 (0.50, 144)
|
0.55
|
Random
|
63.8
|
0.063
|
|
Studies from Europe
|
3
|
0.85 (0.76, 0.95)
|
0.005
|
Fixed
|
12.8
|
0.32
|
